Evrópusambandið - eistneska - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - tsüstiline fibroos - muud hingamisteede tooted - orkambi tabletid on näidustatud ravi tsüstilise fibroosi (cf) patsientidel vanuses 6 aastat ja vanemad, kes on homozygous jaoks f508del mutatsioon cftr geeni. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Eistland - eistneska - Ravimiamet

aspen pharma trading limited - melfalaan - õhukese polümeerikattega tablett - 2mg 25tk

Evrópusambandið - eistneska - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - tsüstiline fibroos - muud hingamisteede tooted - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Evrópusambandið - eistneska - EMA (European Medicines Agency)

teva pharma b.v. - pioglitasoonvesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. pärast algatamist ravi pioglitazone, patsiente tuleks läbi vaadata pärast 3 kuni 6 kuud hinnata piisavust ravi (e. vähendada hba1c). patsientidel, kes ei näita piisava vastuse, pioglitazone tuleks lõpetada. arvestades võimalikke riske pikaajalise ravi, arstid tuleks kinnitada järgmiste korraliste kommentaare, mis kasu pioglitazone on hooldatud.

Evrópusambandið - eistneska - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - tsüstiline fibroos - muud hingamisteede tooted - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Eistland - eistneska - Ravimiamet

chanelle pharmaceuticals manufacturing limited - prasikvanteel+febanteel+püranteel - tablett - 175mg+525mg+175mg 208tk; 175mg+525mg+175mg 80tk; 175mg+525mg+175mg 96tk; 175mg+525mg+175mg 250tk; 175mg+525mg+175mg 48tk; 175mg+525mg+175mg 120tk; 175mg+525mg+175mg 180tk; 175mg+525mg+175mg 52tk; 175mg+525mg+175mg 204tk; 175mg+525mg+175mg 24tk; 175mg+525mg+175mg 140tk; 175mg+525mg+175mg 16tk; 175mg+525mg+175mg 2tk; 175mg+525mg+175mg 300tk; 175mg+525mg+175mg 206tk; 175mg+525mg+175mg 56tk; 175mg+525mg+175mg 112tk; 175mg+525mg+175mg 98tk; 175mg+525mg+175mg 70tk; 175mg+525mg+175mg 10tk; 175mg+525mg+175mg 108tk; 175mg+525mg+175mg 8tk; 175mg+525mg+175mg 100tk; 175mg+525mg+175mg 84tk; 175mg+525mg+175mg 72tk; 175mg+525mg+175mg 60tk; 175mg+525mg+175mg 30tk; 175mg+525mg+175mg 32tk; 175mg+525mg+175mg 12tk; 175mg+525mg+175mg 4tk; 175mg+525mg+175mg 76tk; 175mg+525mg+175mg 500tk; 175mg+525mg+175mg 92tk; 175mg+525mg+175mg 106tk; 175mg+525mg+175mg 20tk; 175mg+525mg+175mg 18tk; 175mg+525mg+175mg 50tk; 175mg+525mg+175mg 14tk; 175mg+525mg+175mg 6tk; 175mg+525mg+175mg 1000tk; 175mg+525mg+175mg 40tk

Eistland - eistneska - Ravimiamet

chanelle pharmaceuticals manufacturing limited - prasikvanteel+febanteel+püranteel - tablett - 175mg+525mg+175mg 206tk; 175mg+525mg+175mg 52tk; 175mg+525mg+175mg 72tk; 175mg+525mg+175mg 208tk; 175mg+525mg+175mg 8tk; 175mg+525mg+175mg 70tk; 175mg+525mg+175mg 98tk; 175mg+525mg+175mg 76tk; 175mg+525mg+175mg 1000tk; 175mg+525mg+175mg 108tk; 175mg+525mg+175mg 16tk; 175mg+525mg+175mg 50tk; 175mg+525mg+175mg 42tk; 175mg+525mg+175mg 100tk; 175mg+525mg+175mg 104tk; 175mg+525mg+175mg 120tk; 175mg+525mg+175mg 180tk; 175mg+525mg+175mg 30tk; 175mg+525mg+175mg 36tk; 175mg+525mg+175mg 200tk; 175mg+525mg+175mg 80tk; 175mg+525mg+175mg 92tk; 175mg+525mg+175mg 60tk; 175mg+525mg+175mg 116tk; 175mg+525mg+175mg 5tk; 175mg+525mg+175mg 6tk; 175mg+525mg+175mg 280tk; 175mg+525mg+175mg 18tk; 175mg+525mg+175mg 112tk; 175mg+525mg+175mg 250tk; 175mg+525mg+175mg 84tk; 175mg+525mg+175mg 204tk; 175mg+525mg+175mg 96tk; 175mg+525mg+175mg 150tk; 175mg+525mg+175mg 12tk; 175mg+525mg+175mg 44tk; 175mg+525mg+175mg 64tk; 175mg+525mg+175mg 56tk; 175mg+525mg+175mg 500tk; 175mg+525mg+175mg 140tk; 175mg+525mg+175mg 300tk; 175mg+525mg+175mg 48tk;

Eistland - eistneska - Ravimiamet

pharmaswiss ceska republika s.r.o. - vankomütsiin - infusioonilahuse pulber - 1000mg 1tk; 1000mg 10tk

Eistland - eistneska - Ravimiamet

pharmaswiss ceska republika s.r.o. - vankomütsiin - infusioonilahuse pulber - 500mg 10tk

Evrópusambandið - eistneska - EMA (European Medicines Agency)

theratechnologies europe limited - ibalizumab - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - trogarzo, koos muu retroviirusevastase(s), on näidustatud ravi täiskasvanud nakatunud multidrug resistentse hiv-1 nakkus, kelle puhul on muul viisil ei ole võimalik luua pärssivat viirusevastane raviskeemi.